KRAS and non-small cell lung carcinoma: More recently, several inhibitors specifically binding mutant KRAS-G12C have been investigated in clinical trials; among these, Sotorasib is the first treatment to gain approval as second-line therapy for adults with NSCLC whose tumors have KRAS-G12C mutation [23,24,25,26,27].